Denali Therapeutics (DNLI) Operating Leases (2019 - 2026)

Denali Therapeutics (DNLI) has 8 years of Operating Leases data on file, last reported at $24.7 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 42.65% year-over-year to $24.7 million in Q1 2026; TTM through Mar 2026 was $24.7 million, a 42.65% decrease from a year earlier, with the FY2025 full-year figure at $27.2 million, down 25.8% from the prior year.
• Operating Leases for Q1 2026 stood at $24.7 million, down from $27.2 million in the prior quarter.
• Over the last five years, Operating Leases for DNLI reached as high as $62.0 million in Q3 2022 and fell as low as $24.7 million in Q1 2026.
• Historically, Operating Leases has averaged $45.4 million across 5 years, with a median of $46.9 million in 2024.
• Across the five-year window, Operating Leases grew 3.43% in 2022 and sank 42.65% in 2026, its largest moves.
• Year by year, Operating Leases stood at $53.0 million in 2022, then slipped by 15.18% to $45.0 million in 2023, then dropped by 18.47% to $36.7 million in 2024, then fell by 25.8% to $27.2 million in 2025, then fell by 9.3% to $24.7 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $24.7 million in Q1 2026, $27.2 million in Q4 2025, and $29.7 million in Q3 2025.